MYOCARDITIS FROM THE mRNA COVID-19 VACCINE
Keywords:
mRNA COVID-19 vaccine, myocarditisAbstract
The Messenger Ribonucleic acid (mRNA) vaccine is the most effective type of vaccine against COVID-19 infection, demonstrating over 90% efficacy in preventing COVID-19 infection and reducing the severity and mortality of the disease. It is recommended for use in the population aged 12 years and older. The most concerning adverse event after mRNA vaccination is myocarditis. Although the mechanism of myocarditis after vaccination is still unknown, it is primarily observed in males younger than 30 years old, often related to the second dose of vaccine, and consistently occurring within 3 to 7 days. Common symptoms include chest pain, shortness of breath, and sensations of
a fast, fluttering, or pounding heart. Adverse events are rare; however, heart failure and shock occur in severe cases. Cardiac MRI may show irregular EKG and Cardiac enzyme is abnormal. Most myocarditis cases are completely reversible. Compared with the advantages of mRNA vaccination against COVID-19 infection, it is recommended. However, individuals at a high risk of myocarditis should consult medical professionals to assess the risk-benefit ratio before vaccination.
Downloads
References
Center for Disease Control and Prevention. (2023). Myocarditis and pericarditis after mRNA COVID-19 vaccination. Retrieved from https://www.CenterforDiseaseControlandPrevention.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html
Department of Disease Control. (2021). Guidelines for COVID-19 vaccination in the outbreak situation in 2021 in Thailand, 1st revised edition. Retrieved from https://tmc.or.th/covid19/download/pdf/covid-19-public-Vaccine-040664.pdf
Department of Disease Control. (2023). Weekly COVID-19 patient situation within the country. Retrieved from https://ddc.moph.go.th/covid19-dashboard/
Expert Panel on Adverse Events Following Vaccination Thai Cardiology Association under the Bureau of Epidemiology, Department of Disease Control. (2021). Myocarditis and pericarditis after mRNA vaccination. Bureau of Epidemiology, Department of Disease Control, Ministry of Public Health. Retrieved from https://www.dropbox.com/s/cuxgk4348rwjnnz/Vaccine%20induced%20myocarditis_Jul29_2021_Final_v2.pdf?dl=0&fbclid=IwAR2xPffHZ-bGjBIOBBJfuA4vL5Yh0XYzAwJZkS3EHT2qrLakEM27bCOm2_Y
Heidecker, B., Dagan, N., Balicer, R., Eriksson, U., Rosano, G., Coats, A., . . . Lüscher, T. F. (2022). Myocarditis following COVID-19 vaccine: Incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial Diseases. European Journal of Heart Failure, 24(11), 2000–2018. https://doi.org/10.1002/ejhf.2669
Ling, R. R., Ramanathan, K., Tan, F. L., Tai, B. C., Somani, J., Fisher, D., & MacLaren, G. (2022). Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: A systematic review and meta-analysis. The Lancet, Respiratory Medicine, 10(7), 679–688. https://doi.org/10.1016/S2213-2600(22)00059-5
Straus, W., Urdaneta, V., Esposito, D.B., Mansi, J. A., Rodriguez, C. S., Burton, P., & Vega, J. M. (2021). Myocarditis after mRNA-1273 vaccination: A population-based analysis of 151 million vaccine recipients worldwide. Clinical Infectious Disease, 70(3), e544-e552. https://doi.org/10.1093/cid/ciac446
Su, J. R. (2021). Myopericarditis following COVID-19 vaccination: Updates from the vaccine adverse event reporting system (VAERS). Retrieved from https://stacks.cdc.gov/view/cdc/109492
Thitichai, P., & Taweewiyakarn, P. (2021). Report on the results of reviewing the COVID-19 disease situation and preventive control measures at the global level and in Thailand. Bureau of Epidemiology, Department of Disease Control, Ministry of Public Health. Retrieved from http://www.thaincd.com/document/file/download/knowledge/COVID19.65.pdf
Wongrachit, K. (Ed.). (2022). Endemic approach to COVID-19. Strategy and Planning Division, Office of Permanent Secretary.
World Health Organization. (2023). Coronavirus disease (COVID-19) pandemic. Retrieved from https://www.WorldHealthOrganization.int/emergencies/diseases/novel-coronavirus-2019
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 JOURNAL OF THE POLICE NURSES
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ผลงานที่ได้ตีพิมพ์แล้วจะเป็นลิขสิทธิ์ของวารสารพยาบาลตำรวจ
